

1 **SENATE FLOOR VERSION**

February 18, 2026

2 **AS AMENDED**

3 SENATE BILL NO. 1344

By: Rosino, Mann, and Hicks of  
the Senate

4 and

5 Stinson of the House

6  
7  
8 **[ prescription drugs - Program - financial support -**  
9 **agreement - codification - effective date -**  
10 **emergency ]**

11 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

12 SECTION 1. NEW LAW A new section of law to be codified  
13 in the Oklahoma Statutes as Section 1-271 of Title 63, unless there  
14 is created a duplication in numbering, reads as follows:

15 A. There is hereby created the Insulin Access and Affordability  
16 Program, which shall be administered by the State Department of  
17 Health for the purpose of increasing patient access to affordable  
18 insulin in this state, increasing marketplace competition, and  
19 addressing shortages in the market for generic insulin.

20 B. The Department shall, with funds appropriated by the  
21 Legislature, provide financial support to a nonprofit pharmaceutical  
22 manufacturer that is currently developing a fast-acting biosimilar  
23 insulin.

1 C. Prior to disbursement of any funds, the Department shall  
2 enter into a memorandum of understanding (MOU) with the nonprofit  
3 pharmaceutical manufacturer and the manufacturer shall demonstrate a  
4 match of non-state funds equal to the amount provided under this  
5 section. The MOU shall include:

6 1. A commitment by the manufacturer to produce a fast-acting  
7 biosimilar insulin at a low net cost without rebates except as  
8 required by law;

9 2. Estimated savings from the purchase of low-cost, fast-acting  
10 biosimilar insulin including, but not limited to, the estimated  
11 savings to residents of this state and public and private payors  
12 from the availability of low-cost, fast-acting biosimilar insulin;

13 3. Provisions related to the repayment of the funds provided  
14 under this section should the manufacturer fail to produce and  
15 distribute a low-cost, fast-acting biosimilar insulin; and

16 4. Annual reporting by the manufacturer to the Department on  
17 the development of the fast-acting biosimilar insulin.

18 SECTION 2. This act shall become effective July 1, 2026.

19 SECTION 3. It being immediately necessary for the preservation  
20 of the public peace, health or safety, an emergency is hereby  
21 declared to exist, by reason whereof this act shall take effect and  
22 be in full force from and after its passage and approval.

23 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS  
24 February 18, 2026 - DO PASS AS AMENDED